Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Schwann cells modulate nociception in neurofibromatosis 1
Namrata G.R. Raut, Laura A. Maile, Leila M. Oswalt, Irati Mitxelena, Aaditya Adlakha, Kourtney L. Sprague, Ashley R. Rupert, Lane Bokros, Megan C. Hofmann, Jennifer Patritti-Cram, Tilat A. Rizvi, Luis F. Queme, Kwangmin Choi, Nancy Ratner, Michael P. Jankowski
Namrata G.R. Raut, Laura A. Maile, Leila M. Oswalt, Irati Mitxelena, Aaditya Adlakha, Kourtney L. Sprague, Ashley R. Rupert, Lane Bokros, Megan C. Hofmann, Jennifer Patritti-Cram, Tilat A. Rizvi, Luis F. Queme, Kwangmin Choi, Nancy Ratner, Michael P. Jankowski
View: Text | PDF
Research Article Neuroscience

Schwann cells modulate nociception in neurofibromatosis 1

  • Text
  • PDF
Abstract

Pain of unknown etiology is frequent in individuals with the tumor predisposition syndrome neurofibromatosis 1 (NF1), even when tumors are absent. Nerve Schwann cells (SCs) were recently shown to play roles in nociceptive processing, and we find that chemogenetic activation of SCs is sufficient to induce afferent and behavioral mechanical hypersensitivity in wild-type mice. In mouse models, animals showed afferent and behavioral hypersensitivity when SCs, but not neurons, lacked Nf1. Importantly, hypersensitivity corresponded with SC-specific upregulation of mRNA encoding glial cell line–derived neurotrophic factor (GDNF), independently of the presence of tumors. Neuropathic pain-like behaviors in the NF1 mice were inhibited by either chemogenetic silencing of SC calcium or by systemic delivery of GDNF-targeting antibodies. Together, these findings suggest that alterations in SCs directly modulate mechanical pain and suggest cell-specific treatment strategies to ameliorate pain in individuals with NF1.

Authors

Namrata G.R. Raut, Laura A. Maile, Leila M. Oswalt, Irati Mitxelena, Aaditya Adlakha, Kourtney L. Sprague, Ashley R. Rupert, Lane Bokros, Megan C. Hofmann, Jennifer Patritti-Cram, Tilat A. Rizvi, Luis F. Queme, Kwangmin Choi, Nancy Ratner, Michael P. Jankowski

×

Figure 3

Chemogenetic activation of SCs induces peripheral hypersensitivity.

Options: View larger image (or click on image) Download as PowerPoint
Chemogenetic activation of SCs induces peripheral hypersensitivity.
(A) ...
(A) DhhCre hM3Dq mice expressing DREADD reporter (top left) and mCitrine in SCs (yellow) surrounding putative NeuN+ neurons (purple) in DRGs (top right). SC cultures from DhhCre hM3Dq mice treated with CNO (40 μM) display enhanced calcium fluorescence (Fluo-4) compared with untreated cultures (bottom left and right, and bar graph, scale bar = 100 μm) (****P < 0.0001 vs. no treatment, t = 14.44, df = 148; t test; mean ± SEM). (B) Treatment of DhhCre hM3Dq mice (n = 5) for 7 days with CNO (2 mg/kg, i.p. once/d) induces mechanical hypersensitivity compared with CNO-treated controls (n = 8) by R-S (*P < 0.05 vs. hM3Dq after CNO, 2-way ANOVA with Tukey’s post hoc; mean ± SEM). (C) Similar results are also seen using the MCA assay (*P < 0.05 vs. hM3Dq after CNO, 1-way ANOVA with Tukey’s post hoc; mean ± SEM). (D) Ex vivo recording of saphenous afferents indicates reduced mechanical thresholds in CPM fibers in CNO-treated DhhCre hM3Dq mice (n = 12 CPMs) compared with controls (n = 12 CPMs) (*P < 0.05 vs. hM3Dq, 1-way ANOVA with Tukey’s post hoc; mean ± SEM). (E) Enhanced firing over increasing forces (stimulus encoding) observed in control CPMs was not found in the DhhCre hM3Dq CPMs. ^P = 0.0038, DhhCre hM3Dq vs. hM3Dq. (F) Area under the curve for firing rates for CPMs. *P < 0.05, 1-way (A, C, D, and F) or 2-way RM (B and E) ANOVA with Tukey’s post hoc as appropriate; mean ± SEM. (G) Example firing patterns of CPM neurons from DhhCre hM3Dq and hM3Dq mice after 7days of CNO injections.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts